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Summary Objectives Unsatisfactory efficacy of current
treatments for advanced lung cancer has prompted the
search for new therapies, with sorafenib, a multikinase
inhibitor, being one candidate drug. This phase I trial was
conducted to evaluate drug safety and pharmacokinetics as
well as tumor response of sorafenib in combination with
paclitaxel and carboplatin in patients with advanced non-
small cell lung cancer (NSCLC). Methods Eligible patients
received paclitaxel (200 mg/m
2) and carboplatin (area
under the curve [AUC]of 6 mg min mL
−1)o nd a y1a n d
sorafenib (400 mg, twice daily) on days 2 through 19 of a
21-day cycle. Results Four of the initial six patients
(cohort 1) experienced dose-limiting toxicities (DLTs),
resulting in amendment of the treatment protocol. An
additional seven patients (cohort 2) were enrolled, two of
whom developed DLTs. DLTs included erythema multi-
forme, hand-foot skin reaction, and elevated plasma
alanine aminotransferase in cohort 1 as well as gastroin-
testinal perforation at a site of metastasis and pneumonia
in cohort 2. Most adverse events were manageable. One
complete and six partial responses were observed among
the 12 evaluable patients. Coadministration of the three
drugs had no impact on their respective pharmacokinetics.
Conclusion The present study confirmed that sorafenib at
400 mg once daily in combination with carboplatin AUC
5m gm i nm L
−1 and paclitaxel 200 mg/m
2 is feasible in
Japanese patients with advanced NSCLC. The results of
this study also showed that this combination therapy had
encouraging antitumor activity and was not associated
with relevant pharmacokinetic interaction in Japanese
NSCLC patients.
Keywords Carboplatin.Lungcancer.Paclitaxel.
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Introduction
Non–small cell lung cancer (NSCLC) accounts for ~75%
of all lung cancers and is the most common cause of
cancer-related deaths worldwide [1]. Individuals with
metastatic NSCLC are candidates for palliative systemic
chemotherapy that confers only a limited survival benefit
[2, 3]. The dismal outlook for patients with advanced
NSCLC who receive currently available therapies has
prompted a search for new, more effective chemothera-
peutic agents and combination regimens. Target-based
therapies are therefore being pursued as potential treat-
ment alternatives.
Sorafenib (BAY 43-9006; Nexavar; Bayer HealthCare,
Montville, NJ; Onyx Pharmaceuticals, Emeryville, CA), is
an oral multikinase inhibitor that inhibits Raf serine-
threonine kinases and several receptor tyrosine kinases
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Ras-Raf-MEK-ERK signaling pathway plays a pivotal
role in the regulation of tumor cell growth by relaying
signals from the cell surface to the nucleus, with the
components of this pathway, including Raf, thus repre-
senting potential targets for anticancer treatment [5, 6].
Sorafenib also targets the vascular endothelial growth
factor (VEGF) receptors VEGFR-2 and VEGFR-3 as well
as platelet-derived growth factor receptor–β (PDGFR-β),
the ligands for which (VEGF and PDGF) are pro-
angiogenic factors essential for tumor growth and metas-
tasis [4]. Sorafenib has recently been approved for
treatment of advanced renal cell carcinoma and hepato-
cellular carcinoma in the United States, Europe, and
several other countries. Furthermore, sorafenib is currently
undergoing clinical evaluation for a variety of additional
cancers, including NSCLC.
Although several phase I clinical trials of sorafenib alone
or in combination with other drugs have been conducted
[7–19], no such phase I study for a specific type of lung
cancer has been performed. The aim of the present phase I
study was to evaluate the safety and pharmacokinetics of
sorafenib in combination with carboplatin and paclitaxel in
patients with advanced NSCLC.
Patients and methods
Patient selection
Eligible patients were 18 years of age or older with
unresectable NSCLC, as confirmed histologically or cyto-
logically, and with a life expectancy of at least 12 weeks.
They were required to be naïve to chemotherapy and to
have an Eastern Cooperative Oncology Group performance
status of 0 or 1. The eligibility criteria also included
adequate bone marrow, hepatic, and renal function as well
as normal blood coagulation parameters. Individuals were
excluded if they had previous or concurrent cancer distinct
in primary site or histology from NSCLC or any cancer
curatively treated >3 years prior to study entry; clinically
active or significant cardiovascular disease; human immu-
nodeficiency virus infection, chronic hepatitis B or C, or
other serious infections; a seizure disorder requiring
medication; a history of organ allograft, substance abuse,
or medical, psychological, or social conditions that might
interfere with participation in the study; or allergy to the
study treatment. Pregnant or breast-feeding patients were
also excluded. All patients received information regarding
the nature and purpose of the study, and they provided
written informed consent in accordance with institutional
guidelines. The study protocol was approved by the
Institutional Review Board of Kinki University Hospital.
Study design
The study was designed as a single-center, open-label, non–
placebo-controlled phase I trial to define the safety,
tolerability, pharmacokinetics, and tumor response profile
of sorafenib administered according to a dosing schedule of
18 days on and 3 days off and in combination with
paclitaxel and carboplatin chemotherapy in chemonaïve
patients with advanced NSCLC. The other phase I trial of
sorafenib in combination with paclitaxel and carboplatin
had already confirmed the safety of sorafenib 400 mg twice
daily in combination with paclitaxel at 225 mg/m
2 and
carboplatin at area under the curve [AUC] of 6 mg min
mL
−1 in a dose-escalation manner [16]. Based on this
result, the starting doses of the present study were decided
as follows; Paclitaxel (200 mg/m
2, infused over 3 h) and
carboplatin (AUC 6 mg min mL
−1 during infusion for
30 min) were administered consecutively on day 1, and
sorafenib (400 mg, twice daily) was administered for
18 days starting on day 2. There was a concern that
sorafenib may inhibit cytochrome P450 enzymes responsi-
ble for the clearance of paclitaxel. Based on this possible
pharmacokinetic interaction and antagonistic effects, sor-
afenib administration was discontinued for two days (days
20 and 21) before the next administration of paclitaxel in
both the present study and the other phase I trial [16]. This
treatment cycle was repeated every 21 days until unaccept-
able toxicity, tumor progression, or death occurred.
Carboplatin-paclitaxel chemotherapy was not allowed to
exceed six cycles, after which sorafenib administration
could continue until the occurrence of intolerable toxicity,
disease progression. If fewer than two of the first six
patients experienced dose limiting toxicity (DLT) in the
first cycle, the dose level was to be recommended for
subsequent clinical trials and an additional six patients were
to be enrolled to the cohort.
Patient evaluation
All observations pertinent to the safety of sorafenib were
recorded, including results of physical examinations, vital
signs, adverse events, use of concomitant medications, and
laboratory test data. Patients were routinely monitored for
adverse events, which were recorded with severity and
relation to study medication according to the National
Cancer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. Assessment of the
chest and abdomen for tumors was performed radiological-
ly (computed tomography or magnetic resonance imaging)
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) [20]. The same radiological method was
performed to maintain consistency of evaluation. Patients
for whom antitumor efficacy (complete or partial response)
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treated according to the study protocol. Measurements were
repeated in patients with a complete or partial response at a
time more than 4 weeks after the response criteria were first
met in order to confirm tumor response according to
RECIST.
Pharmacokinetics
To investigate the effect of paclitaxel-carboplatin on the
pharmacokinetics of sorafenib, we collected blood samples
on days 2 and 19 of treatment cycle 1 for cohort 1 and
determined the plasma concentration of sorafenib. On both
days, samples were collected at 0 h (pre–morning dose of
sorafenib); at 0.5, 1, 3, 6, and 12 h (pre–evening dose); and
at 24 h (pre–morning dose on day 3). After dosing on day
19, additional samples were collected at 48 and 72 h
(before infusion of paclitaxel in cycle 2). The evening dose
of sorafenib was not administered on day 19 of cycle 1 for
the purpose of pharmacokinetic sampling. As a result of
amendment to the treatment protocol for cohort 2, a
modified schedule of blood sampling was adopted. For
determination of the plasma concentration of sorafenib,
blood samples were collected at the same time points in
cycle 2 as in cycle 1, with the exception that the blood
sample obtained at 12 h after the morning administration of
sorafenib on day 2 was collected before the evening dose
on day 2 in cohort 2. The concentration of sorafenib in
plasma samples was determined with the use of a validated
high-performance liquid chromatography–tandem mass
spectrometry (LC-MS/MS) assay.
To investigate the effects of sorafenib on the pharmaco-
kinetics of paclitaxel and carboplatin, we collected blood
samples on day 1 of cycle 1 for cohort 1 and determined the
plasma concentrations of carboplatin, paclitaxel, and the
paclitaxel metabolite 6-hydroxy-paclitaxel. Samples were
collected at 0 h, 1.5 h (during paclitaxel infusion), 3 h
(within 5 min before completion of paclitaxel infusion),
3.5 h (within 5 min before completion of carboplatin
infusion), as well as 4, 5, 7, 11, 24, and 48 h. The amended
treatment protocol for cohort 2 was accommodated by
collection of blood samples immediately before, 1.5 h after
the start of, within 5 min before completion of, as well as
0.5, 1, 2, 4, 8, 21, and 45 h after completion of paclitaxel
infusion on day 1 of cycles 1, 2, and 3 for paclitaxel, and
immediately before, within 5 min before completion of, as
well as 0.5, 1, 3, 7, 20, 31, and 44 h after completion of
carboplatin infusion on day 1 of cycles 1, 2, and 3 for
carboplatin. The plasma concentrations of free (unbound)
platinum derived from carboplatin, of paclitaxel, and of 6-
hydroxy-paclitaxel were measured with the use of atomic
absorption spectrophotometry and were validated by LC-
MS/MS assays.
Pharmacokinetic parameters, including the AUC, maxi-
mum concentration (Cmax), and elimination half-life (t1/2),
for sorafenib, paclitaxel, and carboplatin were calculated by
noncompartment analysis as previously described [17].
Results
Patient demographics
A total of 13 chemonaïve patients with advanced NSCLC
was enrolled in the study, six in cohort 1 and seven in
cohort 2. The baseline demographics for all patients are
shown in Table 1. Histological diagnosis revealed that the
most common histology was adenocarcinoma (eight
patients, or 61.5%), followed by large cell carcinoma and
squamous cell carcinoma (each with two patients, or
15.4%).
DLT
Table 2 summarizes the dosing regimens for evaluated
cohorts together with DLTs. The first six patients enrolled
in cohort 1 were treated with 400 mg of sorafenib twice
daily (days 2 to 19) combined with paclitaxel at 200 mg/m
2
and carboplatin at an AUC of 6 mg min mL
−1 (30-min
infusion). Four of these six patients experienced DLTs
during the first cycle of treatment (two with erythema
Table 1 Patient demographics
No. of patients
Total enrolled 13
Cohort 1 6
Cohort 2 7
Age (years)
Median 66
Range 41–76
Sex
Male 9
Female 4
ECOG performance status
04
19
Disease stage
IV 13
Histology
Adenocarcinoma 8
Large cell carcinoma 2
Squamous cell carcinoma 2
Undifferentiated carcinoma 1
ECOG Eastern Cooperative Oncology Group
846 Invest New Drugs (2010) 28:844–853multiforme of grade 3, one with a hand and foot skin
reaction of grade 3, and one with elevation of plasma
alanine aminotransferase [ALT] of grade 3). One of the
patients diagnosed with erythema multiforme developed a
rash of grade 1 on the arms, thigh, and hip on day 5; by day
15, the rash had spread to the entire body with development
of pruritus (grade 3), and histopathologic analysis of skin
biopsy specimens revealed superficial dermal vasodilation
as well as perivascular lymphocyte and plasma cell
infiltration, consistent with erythema multiforme (Fig. 1a,
b). The second patient also developed a localized rash of
grade 1 that appeared in the right lower part of the abdomen
on day 5 and had spread to the entire body with the
development of a high fever on day 12; histopathologic
analysis of skin biopsy specimens again supported a
diagnosis of erythema multiforme. Both patients responded
well to steroid therapy and improved.
Given that the incidence of DLT at the adopted dose
level exceeded that predefined for the maximum tolerated
dose, a modified dose level consisting of 400 mg of
sorafenib once daily (days 2 to 19) combined with
paclitaxel at 200 mg/m
2 and carboplatin at an AUC of
5 mg min mL
−1 (60-min infusion) was evaluated for the
seven additional patients of cohort 2. None of these seven
patients experienced DLT during cycle 1. Intrapatient
escalation of sorafenib dose was allowed if the patient did
not experience DLT in cycle 1 of cohort 2; the dose of
sorafenib was thus increased to 400 mg twice daily from
day 2 to day 19 in subsequent courses. Among the seven
patients who received sorafenib at 400 mg twice daily
combined with paclitaxel (200 mg/m
2) and carboplatin
(AUC of 5 mg min mL
−1), two individuals developed DLT:
one a perforation of the small bowel of grade 4 and one
pneumonia of grade 3. The patient with gastrointestinal
perforation, who had metastases in the left adrenal gland
and small intestine, developed abdominal pain, fever, and
peritonitis 26 days after initiation of sorafenib at 400 mg
twice daily and required emergency surgery. He recovered
after surgery, and pathological examination of the surgical
specimen confirmed the presence of tumor cells at the site
of perforation. Given the marked tumor response of the
patient on radiographic examination, the perforation event
was likely associated with the antitumor effect of the study
treatment.
Safety
All 13 enrolled patients were evaluable for safety analysis.
Treatment-emergent adverse events (Table 3) occurred in all
patients, the most common being hematologic or dermato-
logic in nature, sensory neuropathy, anorexia, and nausea.
Neutropenia of grade 4 occurred in nine (69%) patients
(four in cohort 1 and five in cohort 2). Hand-foot skin
reaction occurred in five patients (three in cohort 1 and two
in cohort 2), hypertension in four patients (two in cohort 1
and two in cohort 2), elevated plasma lipase in four patients
(three in cohort 1 and one in cohort 2), and erythema
multiforme in three patients (two in cohort 1 and one in
cohort 2).
Antitumor activity
Tumor response was evaluated in 12 of the 13 patients
(Fig. 2), with the remaining patient in cohort 2 not being
available for assessment of such response. One patient in
cohort 1 had a confirmed complete response, and six
patients (three in each cohort) had a confirmed partial
response; the overall response rate was thus 58% (95%
confidence interval of 28 to 85%). Five patients, two in
cohort 1 and three in cohort 2, had stable disease.
Cavitation of lung lesions was observed in one patient
(Fig. 1c, d). The median time to disease progression was
5.7 months (95% confidence interval of 4.3 to
20.1 months).
Table 2 Observed DLTs according to dose level
Cohort Paclitaxel
(mg/m
2)
Carboplatin
(mgminmL
−1)
Sorafenib
(mg)
No. of
patients
No. of patients
with DLTs
DLTs
1 200 6 400 twice daily 6 4 Erythema multiforme, grade 3 (n=2)
Hand-foot skin reaction, grade 3 (n=1)
ALT elevation, grade 3 (n=1)
2 (cycle 1) 200 5 400 once daily 7 0 None
2 (cycle 2) 200 5 400 twice daily 7 2 Perforation, GI, small bowel NOS,
grade 3 (n=1)
Infection-lung (pneumonia)
of grade 3 with neutrophil of grade 4 (n=1)
DLTs dose-limiting toxicities, ALT alanine aminotransferase, GI gastrointestinal, NOS not otherwise specified
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Pharmacokinetic analysis for sorafenib in the presence of
paclitaxel and carboplatin (Table 4) was based on the
patients in cohort 1 (cycle 1) and cohort 2 (cycles 1 and 2)
after administration of a single dose (day 2) or multiple
doses (day 19). The increases in mean Cmax from days 2 to
19 were consistent with those in mean AUC0–12, likely
reflecting the long mean t1/2 (20.4 to 26.8 h on day 19). In
cohort 2, the increases in the mean values of AUC0–12 and
Cmax in cycle 2 (400 mg, twice daily) compared with those
in cycle 1 (400 mg, once daily) were consistent with the
increase in sorafenib dosing. At steady state, after multiple
administrations of sorafenib at 400 mg twice daily together
with paclitaxel and carboplatin, the mean values of AUC0–12
and Cmax in cohort 1 (cycle 1, day 19) were 31.3 mg h L
−1
and 4.6 mg/L, respectively, and those in cohort 2 (cycle 2,
day 19) were 39.1 mg h L
−1 and 5.9 mg/L, respectively.
Given that treatment was discontinued after cycle 1 in
four of the six patients in cohort 1, the effects of multiple
doses of sorafenib on the pharmacokinetics of paclitaxel
and carboplatin were evaluated in cohort 2. Pharmacoki-
netic analysis for paclitaxel and carboplatin was performed
during cycle 1 before sorafenib administration and during
cycles 2 and 3 after sorafenib administration (Table 4).
Small increases in the mean AUC and Cmax values for
Fig. 1 Development of erythema multiforme and tumor cavitation in
patients with advanced NSCLC treated with sorafenib in combination
with carboplatin-paclitaxel. a A rash, initially localized to the arms,
thigh, and hip, spread to the entire body. b Hematoxylin-eosin staining
of a skin lesion from the patient shown in (a) revealed infiltration of
inflammatory cells, mostly lymphocytes, around superficial dermal
blood vessels and the epidermal-dermal junction. Liquefaction
degeneration in basal epidermal layers and cavernous transformation
in part of the epidermal squamous cell layer were also observed. c, d
Computed tomography revealed a solid tumor without cavitation in
the right lung of a patient at baseline (c), whereas the same tumor
showed marked central cavitation on day 19 of cycle 1 (d)
848 Invest New Drugs (2010) 28:844–853Table 3 Numbers of patients with treatment-emergent adverse events including those with a CTCAE worst grade of 3 or 4
Event category CTCAE term Cohort 1 Cohort 2
(n=6) (n=7)
CTCAE grade CTCAE grade
Any 3 4 Any 3 4
Allergy/immunology Allergic reaction 2 2 1
Blood/bone marrow Hemoglobin 2 5 3
Leukocytes 5 4 6 3 1
Lymphopenia 2 2 5 3 1
Neutrophils 5 4 7 5
Platelets 3 5 2 1
Cardiac, general Hypertension 2 2 1
Constitutional symptoms Weight loss 1 4 1
Dermatology/skin Erythema multiforme 2 2 1
Hand-foot skin reaction 3 1 2
Rash/desquamation 4 5
Gastrointestinal Anorexia 5 6 3
Dehydration 2 1
Nausea 4 5 1
Perforation, GI, small bowel NOS 1 1
Infection Febrile neutropenia 1 1
Infection with G4 neutrophils, lung (pneumonia) 1 1
Metabolic/laboratory ALT 3 1 1 1
AST 2 1 1
Hypokalemia 1 1
Hyponatremia 2 2
Hypophosphatemia 4 2
Lipase 3 2 1
Neurology Neuropathy, motor 1 1
Neuropathy, sensory 4 6 2
Pulmonary/upper respiratory Dyspnea 1 1 1
CTCAE Common Terminology Criteria for Adverse Events, GI gastrointestinal, NOS not otherwise specified, ALT alanine aminotransferase, AST
aspartate aminotransferase
Fig. 2 Tumor response. Ten of
the 12 evaluable patients
showed tumor shrinkage, with
one individual manifesting a
complete response (−100%)
Invest New Drugs (2010) 28:844–853 849paclitaxel were observed with progress of the cycles;
however, these changes were not significant based on the
inclusion of 1.00 in the 90% confidence interval for the
ratio of AUC or Cmax in cycles 2 or 3 to the corresponding
value in cycle 1. Similar results were obtained for 6-
hydroxy-paclitaxel (data not shown). There were also no
significant differences in the mean AUC or Cmax values of
free platinum when standard chemotherapy was adminis-
tered with or without sorafenib.
Discussion
We have investigated the effects of sorafenib, an oral
multikinase inhibitor, in combination with standard chemo-
therapy (paclitaxel and carboplatin) in chemonaïve individ-
uals with advanced NSCLC. Our results show that
sorafenib can be integrated with the combination of
paclitaxel and carboplatin. In the present study, the dose
of carboplatin had to be capped one dose level lower (AUC
of 5 mg min mL
−1) than is typical for administration of
paclitaxel and carboplatin alone, because four out of six
patients developed DLTs in cohort 1.
Two of the patients with DLTs in cohort 1 experienced
erythema multiforme of grade 3. Previous studies have
reported that most patients receiving sorafenib as mono-
therapy manifested dermatologic toxicities, mostly of grade
1 or 2, including rash or desquamation (18 to 66%), hand-
foot syndrome (25 to 62%), and alopecia (18 to 53%) [15,
21, 22]. Erythema multiforme was reported to occur in only
0.1 to <1% of patients [22, 23]. In the two cases of
erythema multiforme in the present study, skin rashes
occurred within a week after initiation of sorafenib
treatment and spread to the entire body without organ
dysfunction. Histopathologic examination of skin speci-
mens supported the diagnosis of erythema multiforme.
Steroid treatment and discontinuation of sorafenib resulted
in marked improvement of the patients within days. A drug
lymphocyte stimulation test was performed for both
patients, with the results being positive for sorafenib and
Table 4 Pharmacokinetic analysis
Sorafenib Cohort 1 Cohort 2
Cycle 1 Cycle 1 Cycle 2
Day 2
400 mg sd
(n=6)
Day 19
400 mg bid
(n=3)
Day 2
400 mg sd
(n=7)
Day 19
400 mg od
(n=7)
Day 2
400 mg sd
(n=6)
Day 19
400 mg bid
(n=4)
AUC0–12
(mg h L
−1)
18.2 (74) 31.3 (32) 9.0 (82) 24.4 (25) 14.6 (25) 39.1 (51)
Cmax (mg/L) 2.5 (96) 4.6 (36) 1.2 (93) 3.2 (22) 2.0 (21) 5.9 (38)
t1/2 (h) 20.4 (18) 26.8 (41) 23.9 (29)
Paclitaxel Cohort 2
Cycle 1 (n=7) Cycle 2 (n=6) Cycle 3 (n=4)
AUC (mg h L
−1) 27889.1 (36) 29538.6 (23) 34712.8 (51)
Ratio [90% CI] 1.05 [0.88–1.25] 1.26 [1.02–1.55]
Cmax (mg/L) 8016.5 (53) 10076.4 (18) 11218.8 (65)
Ratio [90% CI] 1.19 [0.80–1.77] 1.39 [0.88–2.21]
t1/2 (h) 10.7 (10) 11.1 (6) 11.4 (3)
Free platinum Cohort 2
Cycle 1 (n=7) Cycle 2 (n=6) Cycle 3 (n=4)
AUC (mg
hL
−1)
44.9 (23) 44.4 (25) 38.5 (10)
Ratio [90% CI] 1.00 [0.91–1.10] 0.90 [0.80–1.00]
Cmax (mg/L) 17.5 (36) 17.4 (34) 17.5 (9)
Ratio [90% CI] 0.92 [0.82–1.02] 0.97 [0.85–1.11]
Pharmacokinetic parameters are presented as geometric means (% coefficient of variation). Ratios for AUC and Cmax values of paclitaxel and free
platinum are dose-adjusted ratios in cycles 2 or 3 relative to those in cycle 1
sd single dose, od once daily, bid twice daily, CI confidence interval
850 Invest New Drugs (2010) 28:844–853negative for both paclitaxel and carboplatin, suggesting that
the exanthematous rashes were caused by drug allergy to
sorafenib rather than by dose-dependent toxicity. Indeed,
serious erythema multiforme was not observed in any of the
seven patients in cohort 2, for whom sorafenib was
administered at 400 mg twice daily in cycle 2 and
subsequent cycles. The only differences between the
treatment regimen in cohort 1 and that of cycle 2 and
subsequent cycles in cohort 2 were the dose (AUC) and
infusion time of carboplatin, which were 6 mg min mL
−1
over 30 min and 5 mg min mL
−1 over 60 min, respectively,
and pharmacokinetic analysis revealed that the triplet
regimen had no significant effects on the pharmacokinetics
of the individual agents. These data thus suggest that the
sorafenib-related erythema multiforme observed in cohort 1
was likely the result of classic skin hypersensitivity to the
drug.
Two additional DLTs (hand-foot skin reaction and
elevation of ALT, both of grade 3) were observed in
cohort 1, both of which were manageable and resolved
by treatment interruption and remedial therapy. Al-
though the study treatment was discontinued after the
first cycle in the four patients with DLTs in cohort 1,
one patient showing a partial response received three
cycles of carboplatin-paclitaxel-sorafenib and an addi-
tional 13 cycles of sorafenib maintenance monotherapy,
and another patient showing a complete response
received four cycles of the combination therapy and an
additional 23 cycles of sorafenib monotherapy. A
previous phase I study of sorafenib combined with
paclitaxel and carboplatin for advanced solid tumors
(mostly malignant melanoma) recommended doses for
future trials of sorafenib at 400 mg twice daily,
carboplatin at an AUC of 6 mg min mL
−1,a n d
paclitaxel at 225 mg/m
2. In a recently completed random-
ized phase III study of advanced NSCLC, patients were
randomly assigned to treatment either with sorafenib at
400 mg twice daily plus carboplatin (AUC of 6 mg min
mL
−1) and paclitaxel (200 mg/m
2) or with carboplatin and
paclitaxel alone [24]. The present study suggests that the
dose of sorafenib tolerated by Japanese patients is likely to
be lower than that tolerated by Western patients when this
agent is combined with standard doses of carboplatin and
paclitaxel.
We examined the pharmacokinetics of paclitaxel,
carboplatin, and sorafenib in order to detect any
relevant drug-drug interactions. The pharmacokinetics
of sorafenib in the present combination study were
similar to those described in previous monotherapy [7,
17] and combination [16] trials, in which there was no
evidence of drug-drug interactions. Neither of the carbo-
platin doses administered in the present study (AUC of 5
o r6m gm i nm L
−1) appeared to affect the pharmacokinet-
ics of sorafenib. Furthermore, we have shown for the first
time that administration of sorafenib at 400 mg twice daily
had no effect on the pharmacokinetics of carboplatin.
Whereas small increases in the AUC and Cmax values of
paclitaxel and 6-hydroxy-paclitaxel were observed after
sorafenib administration at 400 mg twice daily, these
increases were not statistically significant. Paclitaxel is
primarily metabolized in the liver by the CYP2C8
pathway to 6-hydroxy-paclitaxel and is also metabolized
by CYP3A4 [25]. Although we are not able to exclude
possible inhibition by sorafenib of the metabolic clearance
of paclitaxel, the observed increase in paclitaxel exposure
was not associated with increased clinical toxicity.
Together, our pharmacokinetic results suggest that con-
comitant administration of sorafenib, carboplatin, and
paclitaxel had no significant impact on the pharmacoki-
netics of any of these three drugs in this treatment
schedule, although our finding on pharmacokinetics will
need to be reproduced in larger cohort of patients treated
with this combination.
Although tumor evaluation was not the primary objec-
tive of our study, the combination treatment yielded
promising results, with one complete response and six
partial responses observed among the 12 evaluable patients.
Despite this substantial antitumor activity observed in the
present study, a phase III trial (ESCAPE: Evaluation of
Sorafenib, Carboplatin, and Paclitaxel Efficacy) of 926
patients with advanced NSCLC receiving first-line therapy
with paclitaxel and carboplatin in the absence or presence
of sorafenib failed to show an improvement in efficacy with
the addition of sorafenib to the standard combination
chemotherapy [24]. Indeed, a subset analysis of the 219
patients with squamous histology was suggestive of a
detrimental effect of sorafenib inclusion. The complete
response and all partial responses in our phase I study
occurred in patients with non-squamous NSCLC. Although
the biological basis for a possible ethnic difference in
sorafenib efficacy and toxicity remains unknown, further
investigation are warranted to identify the patients who are
more likely to benefit from this agent.
In conclusion, in combination with carboplatin AUC
5 mg min mL
−1 and paclitaxel 200 mg/m
2, administration
of sorafenib at 400 mg once daily was confirmed to be
feasible in Japanese patients with advanced NSCLC.
There was no relevant pharmacokinetic interaction and
the observed antitumor activity was encouraging in this
study.
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